Q-omics provides the consensus-scored MAP1LC3B profile across patient tissues and cancer cell-line models. MAP1LC3B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, MAP1LC3B is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, MAP1LC3B RNA expression shows 17,763 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ESCA, KIRP, and UVM as cancer lineages where MAP1LC3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAP1LC3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAP1LC3B survival associations across molecular data types. MAP1LC3B RNA expression shows survival associations in the most cancer types (21), followed by mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAP1LC3B RNA expression–survival associations across cancer types. High MAP1LC3B expression shows unfavorable associations in ESCA, HNSC, BLCA, STAD and SCLC, but favorable associations in KIRC. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify ESCA as the clearest survival context for MAP1LC3B RNA expression.
This table summarizes MAP1LC3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRP for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MAP1LC3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAP1LC3B shows lower tumor expression in UCEC, LUSC, LUAD and BRCA and higher tumor expression in KIRP and HNSC. The KIRP box plot shows higher MAP1LC3B RNA expression in tumor versus normal tissue (log2 FC = +0.922, t-test p < 0.001).
This table shows molecular features associated with MAP1LC3B in patient tissues and cancer cell lines. In patient samples, MAP1LC3B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MAP1LC3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
